Literature DB >> 338039

EEG profile and behavioral changes after a single dose of clozapine in normals and schizophrenics.

J Roubicek, I Major.   

Abstract

Clozapine, a powerful neuroleptic with unique clinical efficacy (and without parkinsonic side effects), has been shown to have an unusual EEG profile. The EEG changes after clozapine, especially when instrumentally quantified, demonstrated the predictive value of EEG. The similarities of the EEG profile of clozapine with the profile of thymoleptic compounds indicated its possible thymoleptic effect. This later proved to be the case with therapeutic studies in depression. The EEG profile of clozapine in volunteers is similar to the EEG profile in schizophrenics (with appropriately higher doses). Instrumental quantification was performed with spectral and iterative interval analysis to show the advantages of each method and also the complementary value of both of them.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 338039

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  8 in total

Review 1.  Clinical experience with clozapine in Germany.

Authors:  H Helmchen
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

2.  Additivities of compounds that increase the numbers of high affinity [3H]muscimol binding sites by different amounts define more than 9 GABA(A) receptor complexes in rat forebrain: implications for schizophrenia and clozapine research.

Authors:  R F Squires; E Saederup
Journal:  Neurochem Res       Date:  2000-12       Impact factor: 3.996

Review 3.  A review of evidence for GABergic predominance/glutamatergic deficit as a common etiological factor in both schizophrenia and affective psychoses: more support for a continuum hypothesis of "functional" psychosis.

Authors:  R F Squires; E Saederup
Journal:  Neurochem Res       Date:  1991-10       Impact factor: 3.996

4.  EEG alterations in patients treated with clozapine in relation to plasma levels.

Authors:  C Haring; C Neudorfer; J Schwitzer; M Hummer; A Saria; H Hinterhuber; W W Fleischhacker
Journal:  Psychopharmacology (Berl)       Date:  1994-02       Impact factor: 4.530

5.  Levomepromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial.

Authors:  Samarthji Lal; Joseph X Thavundayil; N P Vasavan Nair; Lawrence Annable; Ng M K Ng Ying Kin; Antoine Gabriel; George Schwartz
Journal:  J Psychiatry Neurosci       Date:  2006-07       Impact factor: 6.186

6.  State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 - Relation to antipsychotic-like drug effects.

Authors:  Robert W Gould; Michael T Nedelcovych; Xuewen Gong; Erica Tsai; Michael Bubser; Thomas M Bridges; Michael R Wood; Mark E Duggan; Nicholas J Brandon; John Dunlop; Michael W Wood; Magnus Ivarsson; Meredith J Noetzel; J Scott Daniels; Colleen M Niswender; Craig W Lindsley; P Jeffrey Conn; Carrie K Jones
Journal:  Neuropharmacology       Date:  2015-11-23       Impact factor: 5.250

Review 7.  Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia.

Authors:  A Fitton; R C Heel
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

Review 8.  Aberrant neural synchrony in the maternal immune activation model: using translatable measures to explore targeted interventions.

Authors:  Desiree D Dickerson; David K Bilkey
Journal:  Front Behav Neurosci       Date:  2013-12-27       Impact factor: 3.558

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.